unnamed Lab1636 peripheral sensory neuron small molecule

An unnamed **preclinical small molecule** therapeutic candidate being developed by **Lab1636** from work originating in the laboratories of **David Ginty** and **Lauren Orefice** at Harvard Medical School. The program is designed to **modulate or inhibit peripheral sensory neuron activity** to reduce **tactile hypersensitivity** associated with **autism spectrum disorder**, and it has also been described as potentially relevant to **neuropathic pain** and **chronic pain**. The specific molecular target, chemical identity, route of administration, and formulation have not been publicly disclosed. Publicly available descriptions indicate the project advanced from proof-of-concept findings in mouse models into **preclinical development** under the Harvard and Deerfield-backed Lab1636 alliance.

Other names

Lab1636 peripheral sensory neuron small moleculeLab-1636 peripheral sensory neuron small moleculeLab 1636 peripheral sensory neuron small moleculeunnamed preclinical small molecule for tactile hypersensitivity in autism spectrum disorder